10 Notable Biotech Companies With Recent Major VC Rounds

However, there is a notable shift in investment focus. Preclinical companies are receiving less funding, while larger private rounds are becoming more common. Clinical-stage companies, particularly those with experienced management teams, are more likely to succeed in pricing IPOs. The broader economic environment and the Federal Reserve's interest rate policies are influencing these investment patterns. As a result, investors are increasingly considering mergers and acquisitions (M&A) and partnerships as viable exit strategies, given the fluctuating IPO market.

Read also: 13 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 2 Upcoming Public Debuts)

Below we list some of the notable venture capital rounds lately, with a focus on innovative technological platforms or breakthrough biology: 

Asceneuron SA

The company secured $100 million in Series C funding to develop tau-targeting therapies for neurodegenerative diseases, with a focus on phase 2 clinical trials for Alzheimer’s disease. The company’s lead candidate aims to reduce the accumulation of tau protein tangles in the brain, which are associated with the progression of Alzheimer’s. Asceneuron’s therapies are designed to modify disease progression and improve cognitive function.

AusperBio

funding to advance its targeted oligonucleotide therapies, particularly for hepatitis B. The company’s innovative platform designs and develops oligonucleotide-based treatments that target viral RNA, aiming to achieve functional cures for chronic infections. AusperBio’s therapies offer a new approach to treating viral diseases by directly targeting the genetic material of the virus.